Addex to Present at the Swiss Equities Baader Virtual Conference
11 January 2022 - 05:00PM
Geneva, Switzerland, January
11,
2022 - Addex
Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that CEO, Tim Dyer, will
present at the Swiss Equities Baader Virtual Conference taking
place January 12 - 14th, 2022. Yesterday, Baader Helvea Equities
issued an initiation coverage report on Addex with a buy rating,
describing the company as “an underdog stock with potential to hit
a home run”.
In his presentation, which is scheduled for
Friday, January 14, 2021 at 08:40 EST / 14:50 CET, Mr Dyer will
provide a corporate update and discuss recent developments at
Addex. A video of the presentation will be available for viewing
on-demand by registered participants.
Management will be available for virtual
one-on-one meetings throughout the conference. For more information
or to schedule a one-on-one meeting with management, please contact
your conference representative or James@HaydenIR.com.
About Addex
Therapeutics:Addex Therapeutics is a
clinical-stage pharmaceutical company focused on the development
and commercialization of an emerging class of novel orally
available small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is in a pivotal registration
clinical trial for Parkinson’s disease levodopa induced dyskinesia
(PD-LID) and has entered a Phase 2 clinical study for the treatment
of blepharospasm, a form of dystonia. Addex's third clinical
program, ADX71149 (mGlu2 positive allosteric modulator or PAM),
developed in collaboration with Janssen Pharmaceuticals, Inc., is
in a Phase 2a proof of concept clinical trial for the treatment of
epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for
the development of drug candidates with a focus in addiction.
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for
PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for
Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Addex shares are listed on the SIX Swiss Exchange and American
Depositary Shares representing its shares are listed on the NASDAQ
Capital Market, and trade under the ticker symbol "ADXN" on each
exchange.
Contact:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James
CarbonaraHayden IR(646)-755-7412james@haydenir.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including in respect of the
anticipated initiation of clinical trials. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in the Company’s Annual Report on Form 20-F filed with
the SEC on March 11, 2021, as well as market conditions and
regulatory review. Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements.
Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements, except as
required by law.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2023 to Mar 2024